GC376 was the anti-viral protease inhibitor used in the first UC Davis FIP drug trial that took place in 2016.   Smokey was one of 5 FIP cats to be cured in that trial and paved the way for more trials with GS441524.   Both of these drugs are now being trialed for use against COVID-19 in humans.  The groundbreaking work done by Dr's Neil Pedersen and Yunjeong Kim and others that has been saving FIP cats lives for the past year might also save human lives as well.   Supporting FIP research helps cats and humans!

In the article Anivive pledges to continue working for approval of GC376 to treat FIP in cats.   I was fortunate enough to meet Anivive Chief Medical Officer Dr David Bruyette at the Winn Feline Foundation FIP Symposium at UC Davis last November and feel confident Anivive will indeed bring GC376 to market to help end FIP.

‍Anivive Repurposes Veterinary Drug GC376 for COVID-19

‍

‍